Stock Research: Tandem Diabetes

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Tandem Diabetes

NasdaqGM:TNDM US8753722037
4
  • Value
    28
  • Growth
    5
  • Safety
    Safety
    54
  • Combined
    7
  • Sentiment
    14
  • 360° View
    360° View
    4
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Tandem Diabetes Care, Inc. is a global company specializing in insulin delivery and diabetes technology. It operates in the medical device industry, with products including the Tandem Mobi system and the t:slim X2 insulin pump. The company operates globally. In the last fiscal year, the company had a market cap of $1,022 million, profits of $490 million, revenue of $940 million, and 2650 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 4 (better than 4% compared with alternatives), overall professional sentiment and financial characteristics for the stock Tandem Diabetes are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with three out of four indicators below average for Tandem Diabetes. Only the consolidated Value Rank has an attractive rank of 54, which means that the share price of Tandem Diabetes is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is lower than for 54% of alternative stocks in the same industry. All other consolidated ranks are below average. The consolidated Growth Rank has a low rank of 5, which means that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. The consolidated Safety Rank has a riskier rank of 28, meaning the company has a riskier financing structure than 72% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. Finally, professionals are more pessimistic about the stock than for 86% of alternative investment opportunities, reflected in the consolidated Sentiment Rank of 14. ...read more

more
Index
NASDAQ
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 2-Oct-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
54 37 45 17
Growth
5 63 15 79
Safety
Safety
28 15 39 44
Sentiment
14 60 49 12
360° View
360° View
4 36 9 24
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
9 47 21 18
Opinions Change
48 49 50 18
Pro Holdings
n/a 48 49 46
Market Pulse
43 67 67 51
Sentiment
14 60 49 12
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
54 37 45 17
Growth
5 63 15 79
Safety Safety
28 15 39 44
Combined
7 31 17 39
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
46 46 46 15
Price vs. Earnings (P/E)
85 46 56 36
Price vs. Book (P/B)
32 23 39 27
Dividend Yield
1 1 1 1
Value
54 37 45 17
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
45 55 45 57
Profit Growth
14 15 40 100
Capital Growth
49 69 17 19
Stock Returns
5 85 31 93
Growth
5 63 15 79
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
22 37 30 39
Refinancing
77 60 61 33
Liquidity
15 18 43 57
Safety Safety
28 15 39 44

Similar Stocks

Discover high‑ranked alternatives to Tandem Diabetes and broaden your portfolio horizons.

Meta

NasdaqGS:FB
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Intuit

NasdaqGS:INTU
Country: USA
Industry: Application Software
Size: X-Large
Full Stock Analysis

Lithia Motors

NYSE:LAD
Country: USA
Industry: Automotive Retail
Size: X-Large
Full Stock Analysis

Micron

NasdaqGS:MU
Country: USA
Industry: Semiconductors
Size: X-Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.